Anacor Pharmaceuticals (NASDAQ:ANAC)On Monday July 13, 2015 shares of Anacor went up 55%, closing around $131.93 per share after the company announced positive phase 3 results in patients who have atopic dermatitis. There were two phase 3 trials that were testing Anacor’s drug, Crisaborole, for these patients with atopic dermatitis — also known as Eczema. The company wanted to see […]
It’s old hat that biotech ETFs are beating the stock market. But three are new launches flying under the radar of many investors. BioShares Biotechnology Products (NASDAQ:BBP) holds stocks such as Celgene (NASDAQ:CELG) and Anacor Pharmaceuticals (NASDAQ:ANAC) that have shone of late. Two others focus on businesses in the clinical trial stage.http://news.investors.com/071615-762046-small-new-biotechnology-etfs-are-outperforming-peers.htm?ven=yahoocp&src=aurlled&ven=yahoo
View original –
Is Your Biotech ETF Keeping Up With 3 […]
Submitted by Joseph Calhoun via Alhambra Investment Partners,
All that we see or seem is but a dream within a dream.
Edgar Allan Poe
All things are subject to interpretation. Whichever interpretation prevails at a given time is a function of power not truth.
I was walking down the street wearing glasses when the prescription ran out.
I think one of the hardest […]
The Celgene Corporation (CELG – Analyst Report) – Juno Therapeutics’ (JUNO – Analyst Report) immunotherapy deal worth at least a billion dollars was the main story in the biotech sector this week. While concerns are being raised about the high price tag, the deal just goes to show the growing interest in the field of immunotherapy. Meanwhile, quite a few […]
The growth is just getting started at Biogen Idec (NASDAQ: BIIB ) . OK, so it’s been ongoing for quite some time, but it certainly isn’t about to end anytime soon. The company recently launched Tecfidera for multiple sclerosis in the United States, completed three regulatory filings, is expecting three market launches in 2014, and has major trials releasing data […]
Others note continued opportunity in biotech.Robert Christian, who analyzes hedge funds as head of research at K2 Advisors and Franklin Templeton Solutions, said biotech stock-focused managers stand out as one of his favorite strategies among the few dozen he tracks.Christian’s optimism rests on what he called exciting new technologies that justify higher company valuations.”Biotech used to be about making life […]
By Ben LevisohnBarclays’ Geoff Meacham and Jonathan Eckard are feeling good about biotech stocks like Biogen (BIIB) and Alexion Pharmaceuticals (ALXN) heading into the summer. They explain why:
[The] Nasdaq Biotech Index index has outperformed the broader market eight out of 10 times over the summer period (Memorial Day to Labor Day) and in 2Q/3Q, there are a number of meaningful […]
By Ben LevisohnRBC’s Michael Yee and team aren’t too worried about biotech stocks like Gilead Sciences (GILD), Celgene (CELG), and Biogen Idec (BIIB) despite the biotech sector’s big drop last week:
Biotech felt another volatile pullback (similar to March) in the last week of April, pulling back 9% in a week. Investors had their helmets on as we went right through […]
Friday was almost the complete opposite of Thursday – especially in the NASDAQ. Yesterday we wrote how it was difficult for the NASDAQ to rally without the potent combo of Apple + biotechs, which both suffered yesterday. Today both jumped and the results were predictable. The S&P 500 rallied 1.09% and the NASDAQ 1.29%. We will begin to see more […]
By Ben LevisohnIt’s been a bad, bad week for biotech stocks. The iShares Nasdaq Biotech Index ETF (IBB) had dropped 9.3% this week through Thursday’s close, while Amgen (AMGN), Biogen Idec (BIIB), and Celgene (CELG) also suffered big losses. Evercore ISI’s Mark Schoenebaum notes that the valuations of big biotech companies is trading below that of the S&P 500 for only the […]